USFDA Issues Form 483 with Three Observations for Dr. Reddy’s Visakhapatnam Facility
Dr Reddys Laboratories Ltd · Others (Uncategorized) · 15 Oct 2026, 1:50 am
USFDA Issues Form 483 with Three Observations for Dr. Reddy’s Visakhapatnam Facility The USFDA completed a Pre-Approval Inspection at Dr. Reddy’s Laboratories’ FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, conducted between 8th Oct'26 and 9th Oct'26. Following the audit, the regulator issued a Form 483 containing three observations. Dr. Reddy’s confirmed that it will address all observations within the stipulated timeline.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
